Novartis in Society Integrated Report 2022

How we create value

Through our core business, we improve and extend the lives of millions of people around the world, while creating value for our employees, shareholders and the communities in which we operate.

Click to explore


Novartis is a focused medicines company. More than three quarters of our sales comes from innovative medicines.

We use innovative science to address some of society’s most challenging healthcare issues.

We invest in advanced technology platforms, like radioligand therapy, which offer targeted approaches to fighting disease.

New medicines undergo clinical trials to prove they are safe and effective. Not all succeed. Those that do are submitted to regulators for approval.

10.0 bn

Invested in R&D



Core therapeutic areas

(cardiovascular; immunology; neuroscience; solid tumors; hematology)


Key technology platforms

(chemistry; biotherapeutics; RNA therapy; radioligand therapy; gene & cell therapy)


Ongoing Phase III programs


Approvals in the US, EU, Japan and China

Operations and supply chain

Novartis has more than 380 sites worldwide, including more than 50 manufacturing facilities.

We apply high quality standards to produce safe and effective medicines, while working to keep our people safe and reduce our environmental footprint.

Across our business, we are streamlining and digitizing our operations to improve efficiency and accelerate growth.

72.5 bn

Treatments produced

101 703




Lost-time injury and illness rate

(Novartis employees)


Reduction in greenhouse gas emissions

in our own operations compared with 2016 baseline

Access for patients

We not only discover and develop new medicines, but also find new ways to deliver them to as many people as possible.

Before launching new products, we engage with healthcare systems, patients and other stakeholders to understand their needs.

We sell our medicines primarily to wholesale and retail distributors, hospitals, government agencies and managed healthcare providers.

Through our access strategies, we aim to bring our medicines to patients across the income pyramid.

50.5 bn

Net sales (USD)


Priority geographies

(US, Germany, Japan and China)

54.6 m

Patients reached

through access approaches

Social, financial & economic value

Novartis medicines improve and extend the lives of millions of people around the world.

We generate financial returns for shareholders, provide salaries and other benefits for employees and create economic value through the taxes we pay and our relationships with suppliers and partners worldwide.

743 m

Patients reached with Novartis medicines

(236 m through Innovative Medicines, 453 m through Sandoz and 54 m through our Global Health function)

7.5 bn

Paid in dividends to shareholders


2.0 bn

Total income taxes paid


Topic filter